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Bacteriophages (or just phages) are naturally-occurring viruses that infect and kill 
bacteria. They are remarkably numerous, diverse and easily found, for example in 
sewage and dog faeces.  Each phage typically has a narrow host range, infecting 
only certain strains of a particular bacterial species.  Yet a large majority of bacterial 
species studied to date play host to bacteriophages, explaining the remarkable 
diversity. Phages were discovered just over 100 years ago and were first used to 
treat bacterial infections in domestic animals and people in the 1920s.  Phages 
grown in simple broth cultures of host bacteria were used successfully to treat 
salmonellosis in chickens, bacillary dysentery in children and cutaneous furuncles 
and carbuncles in adult humans.  Phages have been safely administered orally, 
topically, intravenously, directly into infected lesions and via inhaled aerosol.  In 
many parts of the world, interest in bacteriophage therapy waned after penicillin 
became available.  Interest continued in France and parts of Eastern Europe.  In 
Georgia, phages continue to be used to treat human bacterial infections, for example 
diabetic foot ulcers.  During the 1980s, veterinarian H. Williams Smith and 
colleagues investigated phage therapy in the UK.  They sought to prevent and treat 
severe Escherichia coli diarrhoea in calves, piglets and lambs.  In 1987 they showed 
that severe, experimental E. coli diarrhoea in calves could be cured by a single dose 
of 100,000 phage particles and could be prevented by doses as low as 100 particles. 
They obtained their phages from ordinary sewage.  The worsening antimicrobial 
resistance crisis has recently led to resurgent interest in bacteriophage therapy. 
Importantly, phages can kill their host bacteria regardless of whether or not the host 
is antimicrobial drug-resistant. This is because drug resistance usually has nothing to 
do with phage resistance. There has recently been a marked increase in the number 
and quality of research publications dealing with phage therapy, mostly for use in 
human medicine but including some veterinary papers.  A few promising publications 
have described successful, topical phage therapy of Pseudomonas aeruginosa otitis 
externa in dogs. Consequently, a veterinary phage product for treatment of 
Pseudomonas otitis externa in dogs (containing six different bacteriophage strains) 
was licensed and became commercially available in Europe.   There have been 
some proof-of-concept studies.  A New Zealand-based research group showed that 
bacteriophages readily found in sewage could kill a large proportion of different 
uropathogenic canine and feline E. coli strains.  A very recent publication described 
the isolation and characterisation of phages with preferential activity against 
methicillin-resistant Staphylococcus pseudintermedius strains, mainly from Europe 
and North America.  The anti-staphylococcal phages were isolated from canine 
faeces.  Despite the fact that bacteriophages have been used to treat bacterial 
infections for nearly 100 years, surprisingly little has been published about their use 
in companion animals. What has been published looks promising. Bacterial skin 
diseases of dogs (including otitis externa) have been studied the most, although only 
to a small extent at this stage.  Phage therapy represents a promising and potentially 
fruitful area of study for companion animal researchers in the future. 
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